YIDU TECH Secures Consecutive Wins at Leading Hospitals While Partnering for a Joint Lab During CIFTIS, Accelerating Medical AI Adoption

Stock News
Sep 15

On September 14, YIDU TECH (02158) announced that its affiliate, Yidu Cloud (Beijing) Technology Co., Ltd., has won the bid for the Aging and Health Innovation Transformation Construction Project under the National Clinical Research Center for Geriatric Disorders at Xiangya Hospital of Central South University. The project carries a total value of approximately RMB 3.57 million. The Xiangya center stands as a national-level scientific research platform. This success highlights that YIDU TECH's technical expertise in medical AI data governance and clinical research services has once again earned recognition from a top-tier healthcare institution. While the contract amount is modest, the benchmark significance of partnering with this platform is far more prominent.

This latest win is not an isolated case. Just one week earlier, YIDU TECH announced its successful bid for the localization adaptation and upgrade project of the data platform at Shanghai Pulmonary Hospital, with an amount also reaching about RMB 3.57 million. The company's consecutive orders across specialized fields such as respiratory and geriatric diseases, as well as regional data platforms, indicate that its medical AI solutions are accelerating entry into core healthcare scenarios. Notably, the "localization adaptation" direction aligns closely with current policy trends emphasizing self-reliance in medical informatization, suggesting strong potential for sustained growth.

Of even greater interest is the company's strategic move during the China International Fair for Trade in Services (CIFTIS). On September 12, YIDU TECH signed a cooperation agreement with the Beijing Health and Big Data and Policy Research Center to jointly establish a "Smart Clinical Research Joint Laboratory." This collaboration centers on three key areas: compliant utilization of health and medical data, drug clinical trials and medical research services, and cultivation of interdisciplinary talent. Unlike single-project deals, this agreement signifies that YIDU TECH has forged a production-academia-research-education synergy with the public institution under the Beijing Municipal Health Commission, extending its role from a solution provider to a co-builder of industry standards and infrastructure.

The compliant utilization of data governance efficiency remains a critical bottleneck for the large-scale deployment of medical AI. Deep exploration in this domain allows the company to build first-mover advantages. At the signing ceremony, co-founder and CEO Xu Jiming emphasized that the deep advancement of medical AI must be built on a foundation of high-quality data, validated through rigorous clinical and scientific practice.

Looking at recent developments, YIDU TECH's business momentum displays three defining traits: wins are diversifying from single-point to multi-point scenarios, covering respiratory diseases, geriatric conditions, and regional data platforms; collaboration levels are extending from hospital departments to health commission system institutions, amplifying policy alignment; and a clear business roadmap centered on "data governance, clinical research, and compliant utilization" is taking shape.

Industry analysts believe that the steady cadence of contract wins, combined with deep ties to government research bodies, reflects a gradually solidifying growth trajectory. Medical digitalization is a long-cycle track, and by focusing on data governance and its underlying technology infrastructure, YIDU TECH is poised to strengthen its operational base, with medium-to-long-term fundamentals expected to improve steadily.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10
     
     
     
     
Company Name:
Tiger Trade Technology Pte. Ltd.
Email Address:
dpo@itiger.com

Copyright © Tiger Trade Technology Pte. Ltd.

Product offerings in different jurisdictions may vary.

Information contained on this website is general in nature and does not take into account of your investment objectives, financial situation and specific needs. It should not be regarded as an offer to sell, asolicitation to buy, a recommendation or endorsement for any financial product, nor does it constitute an investment forecast, investment return commitments, investment suggestions or other practical operating opinions. Information contained on this website is for reference only and past performance should not be construed as future performance. Investment involves risks. Before you make an investment decision, you should carefully judge and screen whether the information contained on this website is appropriate for your needs, goals and circumstances.

We strive but cannot guarantee the accuracy, completeness, reliability and timeliness of all information on this website, and we are not responsible for any losses caused by the use of or reliance on relevant information.

The products and services offered on the website are subject to applicable laws, regulations and relevant agreements. Please carefully read and agree to the agreements before using our products and services.